Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Capital Expenditures (2016 - 2021)

Phio Pharmaceuticals' Capital Expenditures history spans 10 years, with the latest figure at $30000.0 for Q3 2021.

  • For Q3 2021, Capital Expenditures rose 275.0% year-over-year to $30000.0; the TTM value through Dec 2021 reached $51000.0, up 168.42%, while the annual FY2025 figure was $12000.0, 1100.0% up from the prior year.
  • Capital Expenditures reached $30000.0 in Q3 2021 per PHIO's latest filing, up from $15000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $186000.0 in Q2 2017 to a low of -$8000.0 in Q2 2020.
  • Average Capital Expenditures over 5 years is $25000.0, with a median of $15000.0 recorded in 2017.
  • Peak YoY movement for Capital Expenditures: skyrocketed 680.0% in 2019, then crashed 150.0% in 2020.
  • A 5-year view of Capital Expenditures shows it stood at $15000.0 in 2017, then crashed by 66.67% to $5000.0 in 2018, then surged by 680.0% to $39000.0 in 2019, then plummeted by 97.44% to $1000.0 in 2020, then surged by 2900.0% to $30000.0 in 2021.
  • Per Business Quant, the three most recent readings for PHIO's Capital Expenditures are $30000.0 (Q3 2021), $15000.0 (Q2 2021), and $6000.0 (Q1 2021).